The independent source for health policy research, polling, and news.
1,041-1,060 of 1,317 results
Saving the lives of people with the bleeding disorder can require high doses of expensive blood-clotting factor. Taxpayers foot much of the bill as manufacturers profit enormously.
California鈥檚 health insurers trotted out a heart-healthy character with an ulterior motive 鈥 taking a dig at drugmakers.
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he鈥檚 doing to spur competition and bring down drug prices.
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discusses drug costs with Scott Simon, the host of NPR's Weekend Edition. Listen to the broadcast and read a transcript of that conversation.
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Margot Sanger-Katz of The New York Times discuss the health policy changes included in the just-concluded bipartisan budget deal on Capitol Hill. The panelists also talk about the final enrollment numbers for individual insurance purchased under the Affordable Care Act, and possible drug price proposals in President Donald Trump鈥檚 upcoming budget. Plus, Rovner interviews Andy Slavitt, who this week launched a health care advocacy group called 鈥淭he United States of Care.鈥
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo and Julie Appleby and Sarah Jane Tribble of Kaiser Health News discuss President Donald Trump鈥檚 promises to reduce drug prices in his first State of the Union Address. The panelists also discuss the departure of the director of the Centers for Disease Control and Prevention after conflict-of-interest reports and the efforts by some states to flout the Affordable Care Act.
Amazon, Berkshire Hathaway and JPMorgan Chase & Co. are partnering up to address employee health care costs and improve satisfaction. Can they deliver? And would repackaging health insurance involve drones?
A KHN data analysis finds that the door of opportunities connecting Capitol Hill, the federal government and the drug industry likely spins in Big Pharma鈥檚 favor.
Southern Illinois University鈥檚 medical school has halted all herpes research, one of its most high-profile projects, amid growing controversy over a researcher鈥檚 unauthorized methods offshore and in the U.S.
"We really do have a lot of responsibility and culpability," says one hospital official who is part of a working group trying to address the opioid epidemic. Patients have to expect more pain after surgery and understand the risk of addiction, says another doctor.
The lofty ideas floated and billion-dollar deals sealed at J.P. Morgan鈥檚 elite annual conference stand in stark contrast to the uncertainty that clouds health care outside its confines.
Orders for potassium iodide reportedly jumped after a Jan. 2 war of words between Trump and North Korea鈥檚 Kim Jong-un.
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry鈥檚 agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases 鈥 but he intends to work on that problem.
Fatalities are climbing in states that have been flooded by the deadly opioid fentanyl, but are remaining flat 鈥 or even falling 鈥 in many Western states, where the drug has not yet been as common as other parts of the country.
The Republican senator sent out letters to the Food and Drug Administration and HHS demanding an explanation about a rogue herpes vaccine trial.
This doctor came out of retirement with the goal of treating every patient at high risk for hepatitis C he encounters. The problem is finding them.
漏 2026 KFF